Company intelligence / Profile preview

LIfT BioSciences

London, England, United Kingdomliftbiosciences.com ↗

Ownership: Private
Employees: ~23
Development stage: Preclinical

Overview

Strong preclinical data show that IMANs can directly kill cancer cells and modulate the tumor microenvironment to recruit additional immune responses. The company has not yet reported human clinical results but plans a Phase I trial to demonstrate safety, tolerability, and immune recruitment.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Allogeneic cell therapy (neutrophil-based)Engineered cell therapy (CAR IMANs)Immunomodulatory Alpha Neutrophils (IMANs)
Industry: Biotech

Drug pipeline

4 assets

HER2 CAR-IMANs

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Gift of Life Biologics – sourcing HSC donors for scalable manufacturingUniversity of Galway – clinical trial collaborationHookeBio – R&D/manufacturing support in Ireland

Beyond the preview

Go deeper on LIfT BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIfT BioSciences.

Explore the full profile